ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0264

Roxadustat Treatment Corrects Anemia to Hemoglobin (Hb) Values ≥10 g/dL in the Majority of Patients with Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD)

Session Information

Category: Anemia and Iron Metabolism

  • 200 Anemia and Iron Metabolism

Authors

  • Rastogi, Anjay, David Geffen School of Medicine at UCLA, Los Angeles, California, United States
  • Pecoits-Filho, Roberto, Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States
  • Fishbane, Steven, Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, New York, United States
  • Little, Dustin J., Clinical Research, AstraZeneca, Gaithersburg, Maryland, United States
  • Hardy, Elise, Clinical Research, AstraZeneca, Gaithersburg, Maryland, United States
  • Yu, Kin-Hung Peony, FibroGen Inc., San Francisco, California, United States
  • Provenzano, Robert, Department of Nephrology, Hypertension & Transplantation St. John Hospital & Medical Center, Detroit, Michigan, United States
Background

The KDIGO clinical practice guidelines recommend the treatment of anemia in NDD-CKD patients with Hb <10 g/dL to reduce associated symptoms and prevent the need for red blood cell transfusions. Roxadustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor studied for the treatment of anemia in patients with CKD through increasing erythropoietin synthesis and enhancing iron utilization. We studied the percentage of patients with NDD-CKD treated with roxadustat achieving Hb ≥10 g/dL.

Methods

Patients with Hb <10 g/dL and eGFR <60 mL/min/1.73 m2 were randomized to roxadustat or placebo in 3 pivotal double-blind NDD-CKD trials (OLYMPUS, ANDES and ALPS). The cumulative percentage of patients with Hb ≥10 g/dL for at least 2 consecutive visits was analyzed monthly over 12 months of roxadustat treatment, using the number of patients remaining on roxadustat treatment at each time point as the denominator. Hb values were censored for 6 weeks following rescue therapy.

Results

In total, 2391 patients received roxadustat. Mean Hb at baseline was 9.1 g/dL and mean eGFR was 19.7 mL/min/1.73 m2. Among patients still on roxadustat treatment, the cumulative percentage of patients with Hb ≥10 g/dL for at least two consecutive visits was 38.3%, 75.5%, and 87.0% at months 1, 2, and 3, respectively, and 96.4% at month 6 (Figure). Among patients still receiving roxadustat treatment at 12 months, the cumulative percentage with confirmed Hb ≥10 g/dL was 99.0%.

Conclusion

Roxadustat effectively raised Hb levels in NDD-CKD patients, with over 95% of patients achieving Hb ≥10 g/dL after 5 months of treatment.

Figure

Funding

  • Commercial Support